CompletedNot Applicable

Stellate Ganglion Block in Herpes Zoster

Egypt208 participantsStarted 2020-05-01

Plain-language summary

Patient who will be presented to Tanta University Hospitals complaining of acute herpes zoster with onset of vesicular eruption less than 7 days will be included in this clinical study. Patients will be excluded if they refused participation, had allergy to local anesthetics, coagulopathy, local infection, glaucoma, or neurological deficit. All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the patients will be classified into two groups:- Group I (control group): Patients will receive sham block weekly for three times Group III (SGB group): Patients will receive stellate ganglion block weekly for three times The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of complication will be measured.

Who can participate

Age range60 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who is presented to the pain clinic, diagnosed with acute herpes zoster of the face and/ or neck with onset of vesicular eruption less than seven days Exclusion Criteria: * Patient refusal or un-cooperation * Known history of allergy to local anesthetics * Local infection at the site of the block * Platelet count less than 75,000/ cc * Neurological deficit in the upper limb * Glaucoma * Bradycardia

What they're measuring

Incidence of Post-herpetic neuralgia

Timeframe: within 3 months of the last stellate ganglion block

Trial details

NCT IDNCT04188327

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-02

View on ClinicalTrials.gov More Pain trials